Home › Esophageal Adenocarcinoma › Pennsylvania
Esophageal Adenocarcinoma clinical trials in Pennsylvania
15 studies for Esophageal Adenocarcinoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC-Heritage Valley Health System Beaver, Beaver
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- and 24 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Christiana Care Health System-Concord Health Center, Chadds Ford
- and 14 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05677490Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07221149Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- Alliance Cancer Specialists, PC, Bensalem
- Alliance Cancer Specialists, PC, Doylestown
- Alliance Cancer Specialists, PC, Horsham
- and 4 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07392892A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- University of Pennsylania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
Recruiting
Ages 18 to 89 · All sexes · Updated Sep 11, 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Hershey
- Research Site, Philadelphia
- Research Site, Pittsburgh
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Geisinger Medical Center, Danville
Recruiting
Ages 18 to 89 · All sexes · Updated Jul 1, 2026 · NCT05530343Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT04114136Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT06340711Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT07223424Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 21, 2026 · NCT03539822From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.